Health
Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction – News-Medical.Net
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction. That’s the finding of the EMPEROR-Reduced trial presented in a Hot Line session today at ESC Congress 2020.
The EMPEROR-Reduced trial was designed to evaluate the effects of empagliflozin 10 mg once daily (as compared with placebo) in patients with heart failure and a reduced ejection fraction, with or without diabetes, who were already rece…
-
Noosa News23 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News22 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General18 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business9 hours agoFord CEO makes stunning prediction about artificial intelligence